Contrast-enhanced MR imaging of hand and finger joints in patients with early rheumatoid arthritis: do we really need a full dose of gadobenate dimeglumine for assessing synovial enhancement at 3 T?

PURPOSE: To investigate the diagnostic value of a half dose compared with a full dose of gadobenate dimeglumine in the assessment of synovitis or tenosynovitis in the wrist and finger joints in patients with early rheumatoid arthritis (RA) and a disease activity score greater than 3.2. MATERIALS AND METHODS: With institutional review board approval and informed consent, 57 patients with early RA underwent 3-T magnetic resonance (MR) imaging with two different doses of contrast media. The contrast enhancement was measured in inflamed synovial tissue at half dose (0.05 mmol per kilogram of body weight) and at full dose (0.1 mmol/kg) by using T1-weighted sequences with fat saturation. The differences and the correlation of signal intensities (SIs) at half- and full-dose sequences were compared by using the paired t test and Pearson correlations. Image quality, Rheumatoid Arthritis MRI Score (RAMRIS), and tenosynovitis score on half- and full-dose images were compared by two observers using the Wilcoxon test. Interrater agreement was assessed by using κ statistics. RESULTS: A significant difference in SI was found between half-dose and full-dose gadobenate dimeglumine-enhanced synovial tissue (mean: 914.35 ± 251.1 vs 1022 ± 244.5, P < .001). Because the SI showed high correlation between the ratio at half dose and full dose (r = 0.875), the formula, ratio of synovial enhancement to saline syringe at full dose = 0.337 + 1.070 × ratio of synovial enhancement to saline syringe at half dose, can be used to convert the normalized value of half dose to full dose. However, no difference in RAMRIS (score 0 in 490 of 1026 joints; score 1 in 344; score 2 in 158; and score 3 in 34) or tenosynovitis scores in grading synovitis or tenosynovitis in image quality and in assessment of synovial enhancement was detected between half-dose and full-dose images (P = 1). CONCLUSION: Postcontrast synovial SIs showed high correlation between half dose and full dose, and image quality was rated identically. Therefore, half-dose gadobenate dimeglumine at 3-T MR imaging may be sufficient for assessing synovitis or tenosynovitis in early RA.

Comparison of Gd-DTPA and Gd-BOPTA for studying renal perfusion and filtration.

PURPOSE: To measure the systematic error in perfusion and filtration parameters derived from magnetic resonance (MR) renography caused by protein binding of MR contrast agents. MATERIALS AND METHODS: Eight healthy Danish Landrace pigs were examined with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). In four pigs a bolus of gadopentetate-dimeglumine (Gd-DTPA; no protein binding) was injected, followed by gadobenate-dimeglumine (Gd-BOPTA; 10% protein binding). The order was reversed in the other four pigs. A two-compartment filtration model was generalized to allow for protein binding and fitted to whole-cortex region of interest (ROI) curves. Single-kidney plasma flow and volume, tubular flow (or GFR), and tubular transit time of both agents were compared. RESULTS: The data show a strong systematic underestimation (P < 0.001) in GFR by Gd-BOPTA (33 ± 7.2%), and no significant differences (P > 0.05) in plasma flow (2.2 ± 18%), plasma volume (-1.7 ± 7.8%) and tubular transit time (3.1 ± 7.2%). The order of injection had no significant effect. CONCLUSION: Theory and experiments agree that perfusion parameters of both agents are comparable, whereas GFR is underestimated with Gd-BOPTA due to the dependence of relaxivity on protein content. Hence, GFR cannot be measured with protein-bound contrast agents, but the proposed dual-agent protocol may produce new functional indices measuring protein filtration.

Gd-BOPTA for assessment of myocardial viability on MRI: changes of T1 value and their impact on delayed enhancement.

Gadobenate (Gd-BOPTA), injected at a dose of 0.1 mmol/kg body weight, was compared with gadopentetate (Gd-DTPA), injected at a dose of 0.2 mmol/kg body weight, for delineation of myocardial infarction interindividually in two groups of 26 patients each. Delayed enhancement images were assessed subjectively for image quality, and measured for regional T1 values before, 3 min after and 25 min after the injection of each contrast agent. In the 26 patients who received Gd-BOPTA, T1 values of remote myocardium were 1,070 +/- 125 ms, 358 +/- 78 ms and 562 +/- 108 ms before, 3 min after and 25 min after injection, respectively. Infarcted myocardium values were 1,097 +/- 148 ms, 246 +/- 68 ms and 373 +/- 84 ms and left ventricular blood pool 1,238 +/- 95 ms, 194 +/- 47 ms and 373 +/- 72 ms. In the 26 patients who received Gd-DTPA, T1 values were 1,087 +/- 96 ms, 325 +/- 60 ms and 555 +/- 108 ms for remote myocardium; 1,134 +/- 109, 210 +/- 43 ms and 304 +/- 57 ms for infarcted myocardium; and 1,258 +/- 104 ms, 166 +/- 27 ms and 351 +/- 73 ms for left ventricular blood pool. Delayed enhancement image quality showing myocardial infarction was rated good (54%) and excellent (46%) after Gd-BOPTA, and good (58%) and excellent (42%) after Gd-DTPA (no significant differences). A single dose of Gd-BOPTA compared with a double dose of Gd-DTPA causes similar changes of T1 values in infarcted and remote myocardium and provides fairly similar contrast between infarcted and remote myocardium (0.64 +/- 14 versus 0.71 +/- 11) and slightly higher contrast between left ventricular blood and infarcted myocardium (0.22 +/- 17 versus 0.14 +/- 6; p < 0.05). Administration of 0.1 mmol/kg body weight Gd-BOPTA can provide similar late enhancement images compared with the standard 0.2 mmol/kg body weight dose of Gd-DTPA due to the higher T1 relaxivity associated with the former.

Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T.

The purpose was to evaluate the image quality of high-spatial resolution MRA of the renal arteries at 1.5 T after contrast-agent injection of 0.2 mmol/kg body weight (BW) in an interindividual comparison to 3.0 T after contrast-agent injection of 0.1 mmol/kg BW contrast agent (CA). After IRB approval and informed consent, 40 consecutive patients (25 men, 15 women; mean age 53.9 years) underwent MRA of the renal arteries either at a 1.5-T MR system with 0.2 mmol/kg BW gadobutrol or at a 3.0-T MR scanner with 0.1 mmol/kg BW gadobenate dimeglumine used as CA in a randomized order. A constant volume of 15 ml of these contrast agents was applied. The spatial resolution of the MRA sequences was 1.0 x 0.8 x 1.0 mm(3) at 1.5 T and 0.9 x 0.8 x 0.9 mm(3) at 3.0 T, which was achieved by using parallel imaging acceleration factors of 2 at 1.5 T and 3 at 3.0 T, respectively. Two radiologists blinded to the administered CA and the field strength assessed the image quality and the venous overlay for the aorta, the proximal and distal renal arteries independently on a four-point Likert-type scale. Phantom measurements were performed for a standardized comparison of SNR at 1.5 T and 3.0 T. There was no significant difference (p > 0.05) between the image quality at 3.0 T with 0.1 mmol/kg BW gadobenate dimeglumine compared to the exams at 1.5 T with 0.2 mmol/kg BW gadobutrol. The median scores were between 3 and 4 (good to excellent vessel visualization) for the aorta (3 at 1.5 T/4 at 3.0 T for reader 1 and 2). For the proximal renal arteries, median scores were 3 for the left and right renal artery at 1.5 T for both readers. At 3.0 T, median scores were 3 (left proximal renal artery) and 4 (right proximal renal artery) for reader 1 and 3 (left/right) for reader 2 at 3.0 T. For the distal renal arteries, median scores were between 2 and 3 at both field strengths (moderate and good) for both readers. The kappa values for both field strengths were comparable and ranged between 0.571 (moderate) for the distal renal arteries and 0.905 (almost perfect) for the proximal renal arteries. In the phantom measurements, a 40% higher SNR was found for the measurements at 3 T with gadobenate dimeglumine. High-spatial resolution renal MRA at 3.0 T with 0.1 mmol/kg BW gadobenate dimeglumine yields at least equal image quality compared with renal MRA at 1.5 T with 0.2 mmol/kg BW gadobutrol.

Temporal constraints in renal perfusion imaging with a 2-compartment model.

OBJECTIVE: To assess the required temporal resolution and total acquisition time for renal perfusion and filtration measurements with a 2-compartment model. MATERIAL AND METHODS: Saturation-recovery TurboFLASH perfusion measurements of 15 healthy volunteers were acquired at 1.5 T, with a temporal resolution of 1 second during the first pass and a total acquisition time of 270 seconds. The time courses were then regridded and truncated to yield new data sets with temporal resolutions from 1 to 30 seconds in 1-second increments and with total acquisition times from 30 to 270 seconds in 5-second increments, respectively. Each new dataset was postprocessed by fitting the time courses to a 2-compartment model producing measures of perfusion and filtration: plasma volume (PV), plasma flow (PF), tubular volume (TV), and tubular flow (TF). The effect of reducing the temporal resolution or the total acquisition time was investigated by comparing the model parameters with those obtained at full temporal resolution and acquisition time and quantified by defining a discretization error (DE) and a truncation error (TE), respectively. For each parameter, the required temporal resolution and total acquisition times were defined by demanding a DE and TE of less than 10%. RESULTS: It can be concluded from the analysis of the DE and TE that the acquisition of the parameters PF and TF requires a temporal resolution of at least 4 and 5 seconds, respectively. For the other 2 parameters, a temporal resolution of at least 9 seconds is sufficient. The required total acquisition times for PF and PV were 35 and 85 seconds, whereas for the parameters TF and TV, 230 and 255 seconds, respectively, are required. CONCLUSION: Renal perfusion measurements should be acquired with a temporal resolution of at least 4 seconds. To evaluate the renal excretory function adequately, the total acquisition time should be at least 255 seconds.

Intraindividual comparison of high-spatial-resolution abdominal MR angiography at 1.5 T and 3.0 T: initial experience.

PURPOSE: To prospectively compare three-dimensional (3D) contrast material-enhanced abdominal magnetic resonance (MR) angiography at 1.5 and 3.0 T intraindividually in healthy volunteers. MATERIALS AND METHODS: After institutional review board approval and informed consent were obtained, 15 healthy male volunteers (age range, 24-41 years) underwent one abdominal 3D contrast-enhanced MR angiographic examination each at 1.5 and 3.0 T in random order. Fast 3D gradient-echo sequence with parallel imaging acceleration factor of three was used for MR angiography; acquired spatial resolutions were 1x0.8x1 mm3 (imaging time, 19 seconds) at 1.5 T and 0.9x0.8x0.9 mm3 (imaging time, 18 seconds) at 3.0 T. With the latter, volume of the 3D slab was 8% larger. At 1.5 T, 20-mL bolus of gadobenate dimeglumine was delivered at 2 mL/sec; at 3.0 T, 15-mL bolus was delivered at 2.5 mL/sec. Two blinded radiologists rated image quality of aorta and proximal renal arteries in consensus with five-point scale (4=very good, 0=nondiagnostic) according to sequence and in direct intraindividual comparison. Visibility of proximal and segmental renal arteries was rated with three-point scale (3=completely visible, 1=nonvisible). Signal-to-noise ratio (SNR) was determined with phantoms. For statistical analysis of the SNRs, t tests were used. RESULTS: All MR angiographic measurements were diagnostic. Median score for image quality at both field strengths was 4. Depiction of proximal renal arteries was rated 3 at both field strengths. The visibility of the distal renal arteries was better at 3.0 T (median score, 3) than at 1.5 T (median score, 2). With direct comparison, 3.0-T MR angiography was better in 14 of 15 cases; no field strength was preferred in the other case. Mean SNR was significantly (P<.001) higher at 3.0 T (17.8+/-0.09 [standard deviation]) than at 1.5 T (11.9+/-0.10). CONCLUSION: MR angiography at 3.0 T provided better vessel visibility and SNR than did that at 1.5 T, although voxel size and imaging time were reduced.

Intraindividual comparison of MR-renal perfusion imaging at 1.5 T and 3.0 T.

PURPOSE: The purpose of this study was to intraindividually compare fast gradient-echo semiquantitative renal perfusion measurements at 1.5 Tesla (T) and 3.0 Tesla. MATERIALS AND METHODS: Fifteen healthy male volunteers underwent renal perfusion measurements at 1.5 T and 3.0 T after the bolus injection of 7 mL of Gd-BOPTA. At both field strengths a Saturation-Recovery-fast gradient echo sequence (SR-TurboFLASH) with a temporal resolution of 4 (1.5 T) and 5 (3.0 T) simultaneously acquired slices per second was used. At 3.0 T, a parallel-imaging factor 2 was applied. For postprocessing, semiquantitative perfusion parameters including mean transit time (MTT), time to peak (TTP), and maximal signal intensity (SMax) were determined. The signal-to-noise ratios (SNR) of kidneys and aorta were determined precontrast and after enhancement. The image quality was rated by 2 radiologists. After Bonferroni correction paired t-tests were performed for statistical analysis. RESULTS: All measurements were successfully performed. At 3.0 T, a significant 63% increase in the baseline SNR (P = 0.00005) of the kidneys was found, the peak SNR was also increased though not statistically significant. Because of the higher SNR, the SMax was also significantly (P = 0.005) increased from 406 A.U. to 522 A.U., whereas MTT and TTP were not significantly changed. The image quality was rated very good to good for the 3.0 T images but only good to moderate at 1.5 T. CONCLUSION: Renal perfusion measurements at 3.0 T are feasible and directly benefit from the inherently higher SNR at 3.0 T. The higher SNR also translates into an increased SMax, whereas MTT and TTP are independent of the field strength.

Semiquantitative assessment of first-pass renal perfusion at 1.5 T: comparison of 2D saturation recovery sequences with and without parallel imaging.

OBJECTIVE: The purpose of this study was to assess the feasibility and reliability of measurements performed with true fast imaging with steady-state free precession (FISP) and turbo fast low-angle shot (FLASH) sequences with parallel imaging compared with those obtained with turbo FLASH sequences without parallel imaging in first-pass renal perfusion MRI. SUBJECTS AND METHODS: The subjects in this prospective study were 15 healthy men who volunteered to undergo MRI for acquisition of renal perfusion measurements. Imaging was performed at 1.5 T with the following three techniques after administration of gadobenate dimeglumine at 4 mL/s: saturation recovery (SR) turbo FLASH sequences without parallel imaging, SR turbo FLASH sequences with parallel imaging, and SR true FISP sequences. The spatial resolution was 2.3 x 2.6 x 8 mm with a temporal resolution of four slices per second (turbo FLASH without parallel imaging and true FISP) or six slices per second (turbo FLASH with parallel imaging). The semiquantitative perfusion parameters mean transit time and maximal upslope were determined. Signal-to-noise ratio (SNR), delta ratio, and time to maximal signal intensity also were determined. Image quality was rated in consensus. RESULTS: Image quality was best for turbo FLASH sequences without parallel imaging compared with true FISP and turbo FLASH sequences with parallel imaging. True FISP sequences yielded the highest baseline SNR (26.7) but the lowest delta ratio (3.2). Turbo FLASH sequences without and with parallel imaging had significantly lower SNRs (9.6 and 9.3) and significantly higher delta ratios (5.1 and 5.0). The first-pass perfusion parameters mean transit time and time to maximal signal intensity were independent of the technique used. CONCLUSION: It seems that at 1.5 T, turbo FLASH sequences without parallel imaging are the best approach to renal first-pass perfusion imaging.

Renal perfusion: comparison of saturation-recovery TurboFLASH measurements at 1.5T with saturation-recovery TurboFLASH and time-resolved echo-shared angiographic technique (TREAT) at 3.0T.

PURPOSE: To investigate the dependence of semiquantitative renal perfusion parameters on the acquisition technique and field strength used. MATERIALS AND METHODS: After intravenous injection of 7-mL Gd-chelates, high-temporal-resolution turbo fast low-angle shot (TurboFLASH) renal perfusion measurements were performed on eight healthy volunteers at 1.5T and another eight healthy volunteers at 3.0T. Another eight healthy volunteers were examined at 3.0T using time-resolved echo-shared angiographic technique (TREAT) after bolus administration of 7-mL Gd-chelates with a temporal resolution of 1.4 seconds. Analysis of the first-pass perfusion data yielded the following semiquantitative renal perfusion indices: mean transit time (MTT), time to peak (TTP), maximal upslope (MUS), and maximal signal intensity (MSI). RESULTS: MTT and TTP did not show significant differences between the different techniques. MSI and MUS were significantly (P < or = 0.002) higher with TREAT (591.1 a.u./second and 103.5 a.u./second) than with TurboFLASH at both field strengths (1.5T: 400.5 a.u./second and 65.4 a.u./second; 3.0T: 362.2 a.u./second and 68.7 a.u./second). CONCLUSION: Semiquantitative renal perfusion measurements are feasible with time-resolved echo-shared sequences and TurboFLASH techniques. While MTT and TTP appear to be independent of the technique and field strength applied, MUS and MSI are higher with TREAT.

Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.

OBJECTIVES: We sought to determine the relaxivity and accurate relaxation rates of Gd-DTPA, Gd-BT-DO3A, and Gd-BOPTA at 0.2, 1.5, and 3 T in human blood plasma. MATERIALS AND METHODS: Contrast media concentrations between 0.01 and 16 mM in human plasma were used for relaxation measurements. The R1 and R2 relaxation rates and r1 and r2 relaxivities were determined. RESULTS: Gd-BOPTA produced the highest relaxation rates and relaxivities at all field strengths. The r1 and r2 values for Gd-BOPTA were 107-131% and 91-244% higher than for Gd-DTPA, respectively, and 72-98% and 82-166% higher than for Gd-BT-DO3A. Higher field strengths resulted in lower values of R1, R2, and r1 for all contrast agents tested and of r2 for Gd-DTPA and Gd-BT-DO3A. A linear dependence of R1 and R2 on concentration was found for Gd-DTPA and Gd-BT-DO3A and a nonlinear dependence for Gd-BOPTA for concentrations larger than 1 mM. The r1 and r2 relaxivity of Gd-BOPTA increased with decreasing concentration. CONCLUSIONS: Gd-BOPTA demonstrates the highest longitudinal r1 at all field strengths, which is ascribable to weak protein interaction. The R2/R1 ratio increases at higher field strength only for Gd-BOPTA, hence very short echo times are required for Gd-BOPTA to benefit from the higher longitudinal relaxivity.

Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.

RATIONALE AND OBJECTIVE: The objective of this study was to compare 0.1 and 0.2 mmol/kg body weight (bw) doses gadobenate dimeglumine (Gd-BOPTA; MultiHance) and gadobutrol (Gd-BT-DO3A; Gadovist) for cerebral perfusion magnetic resonance (MR) imaging at 1.5 T. METHODS: Twelve healthy male volunteers enrolled into a randomized intraindividual comparative study underwent 4 perfusion MR imaging examinations with 0.1 and 0.2 mmol/kg bw doses of each contrast agent. The imaging parameters, slice positioning, and contrast agent application were highly standardized. Quantitative determinations based on signal intensity/time (SI/T) curves at regions of interest (ROI) on the gray and white matter were made of the regional cerebral blood volume and flow (rCBV and rCBF, respectively), the percentage signal drop, and the full width half maximum (FWHM) of the SI/T curve. Qualitative evaluation of the quality of the rCBV and rCBF maps was assessed by an independent offsite blinded reader. RESULTS: A single dose of both agents was sufficient to achieve high-quality, diagnostically valid perfusion maps at 1.5 T, and no significant benefit for one agent over the other was noted for quantitative or qualitative determinations. The susceptibility effect, described by percentage of signal loss (gadobutrol: 29.4% vs gadobenate dimeglumine: 28.3%) and the FWHM (gadobutrol: 6.4 seconds vs gadobenate dimeglumine: 7.0 seconds) were similar for 0.1 mmol/kg bw doses of the 2 agents. Double doses of the 2 agents produced better overall image quality but no clinical benefit over the single-dose examinations. CONCLUSION: Both the 1 molar MR contrast agent gadobutrol and the weak protein-interacting agent gadobenate dimeglumine permit the acquisition of high-quality perfusion maps at doses of 0.1 mmol/kg bw. The susceptibility effect is comparable for both agents and stronger than for conventional MR contrast agents.

Regional lung perfusion: assessment with partially parallel three-dimensional MR imaging.

PURPOSE: To evaluate partially parallel three-dimensional (3D) magnetic resonance (MR) imaging for assessment of regional lung perfusion in healthy volunteers and patients suspected of having lung cancer or metastasis. MATERIALS AND METHODS: Seven healthy volunteers and 20 patients suspected of having lung cancer or metastasis were examined with 3D gradient-echo MR imaging with partially parallel image acquisitions (fast low-angle shot 3D imaging; repetition time msec/echo time msec, 1.9/0.8; flip angle, 40 degrees; acceleration factor, two; number of reference k-space lines for calibration, 24; field of view, 500 x 440 mm; matrix, 256 x 123; slab thickness, 160 mm; number of partitions, 32; voxel size, 3.6 x 2.0 x 5.0 mm(3); acquisition time, 1.5 seconds) after administration of 0.1 mmol/kg of gadobenate dimeglumine. In volunteers, 3D MR perfusion data sets were assessed for topographic and temporal distribution of regional lung perfusion. Sensitivity, specificity, accuracy, and positive and negative predictive values for perfusion MR imaging for detecting perfusion abnormalities in patients were calculated, with conventional radionuclide perfusion scintigraphy as the standard of reference. Interobserver and intermodality agreement was determined by using kappa statistics. RESULTS: Topographic analysis of lung perfusion in volunteers revealed a significantly higher signal-to-noise ratio (SNR) of up to 327% in gravity-dependent lung areas. Temporal analysis similarly revealed much shorter lag time to peak enhancement in gravity-dependent lung areas. In patients, perfusion MR imaging achieved high sensitivity (88%-94%), specificity (100%), and accuracy (90%-95%) for detection of perfusion abnormalities. Interobserver agreement (kappa = 0.86) was very good and intermodality agreement (kappa = 0.69-0.83) was good to very good for detection of perfusion defects. A significant difference (P <.0001) in SNR was observed between normally perfused lung (14 +/- 7 [SD]) and perfusion defects (7 +/- 4) in patients. CONCLUSION: Partially parallel MR imaging with high spatial and temporal resolution allows assessment of regional lung perfusion and has high diagnostic accuracy for detecting perfusion abnormalities.

Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

PURPOSE: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis. MATERIALS AND METHODS: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine. MR imaging was performed before injection (T1-weighted spin-echo [SE] and T2-weighted fast SE acquisitions) and at 1, 3, 5, 7, 9, and 16 minutes after injection (T1-weighted SE acquisitions). Qualitative assessment was performed by blinded off-site readers (for 22 patients) and on-site investigators (for 24 patients) in terms of global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference. Additional quantitative assessment with region-of-interest analysis was performed by off-site readers alone. Statistical analysis of qualitative data was performed with the Wilcoxon signed rank test, whereas a nonparametric approach was adopted for analysis of quantitative data. RESULTS: Significant (P <.05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the global assessment of contrast enhancement. For off-site readers 1 and 2 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patients; and equality was found in five, one, and four patients). Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site investigators for lesion-to-brain contrast and all other qualitative parameters. Off-site quantitative evaluation revealed significantly (P <.05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after injection. CONCLUSION: Significantly superior contrast enhancement of intraaxial enhancing brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine.

Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.

RATIONALE AND OBJECTIVES: Gadobenate dimeglumine (Gd-BOPTA) has a two-fold higher T1 relaxivity compared with gadopentetate dimeglumine (Gd-DTPA) and can be used for both dynamic and delayed liver MRI. This intraindividual, crossover study was conducted to compare 0.05 mmol/kg Gd-BOPTA with 0.1 mmol/kg Gd-DTPA for liver MRI. MATERIALS AND METHODS: Forty-one patients underwent two identical MR examinations separated by >or= 72 hours. Precontrast T1-FLASH-2D and T2-TSE sequences and postcontrast T1-FLASH-2D sequences were acquired during the dynamic and delayed (1-2 hours) phases after each contrast injection. Images were evaluated on-site by two independent, blinded off-site readers in terms of confidence for lesion detection, lesion number, character and diagnosis, enhancement pattern, lesion-to-liver contrast, and benefit of dynamic and delayed scans. Additional on-site evaluation was performed of the overall diagnostic value of each agent. RESULTS: Superior diagnostic confidence was noted by on-site investigators and off-site assessors 1 and 2 for 6, 4 and 2 patients with Gd-BOPTA, and for 3, 1 and 2 patients with Gd-DTPA, respectively. No consistent differences were noted for other parameters on dynamic phase images whereas greater lesion-to-liver contrast was noted for more patients on delayed images after Gd-BOPTA. More correct diagnoses of histologically confirmed lesions (n = 26) were made with the complete Gd-BOPTA image set than with the complete Gd-DTPA set (reader 1: 68% vs. 59%; reader 2: 78% vs. 68%). The overall diagnostic value was considered superior after Gd-BOPTA in seven patients and after Gd-DTPA in one patient. CONCLUSION: The additional diagnostic information on delayed imaging, combined with the possibility to use a lower overall dose to obtain similar diagnostic information on dynamic imaging, offers a distinct clinical advantage for Gd-BOPTA for liver MRI.